The clinical rationale derives from the clinical benefit guided by ESR1 mutations in (HR)+/HER2- BC patients treated with selective ER degraders (SERDs) and ER modulators (SERMs) compared with standard of care endocrine monotherapy [6,7]. This evidence concerns the gene ERBB2 and breast cancer.